Sialyl Lewis X-polysaccharide conjugates: targeting inflammatory lesions.
A novel system for active targeting of inflammatory lesions has been established. A SLeX-CMPul conjugate (2) showed accumulation that was 2.5-fold higher in inflammatory lesions in vivo than a SLN-CMPul conjugate (4) and 300-fold higher than monovalent SLeX (6).
Sakagami
M
M
Drug Delivery System Institute, Ltd., Chiba, Japan.
Horie
K
K
Nakamoto
K
K
Kawaguchi
T
T
Hamana
H
H
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D002240:Carbohydrate Sequence; D004337:Drug Carriers; D004487:Edema / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy; D051379:Mice; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D011134:Polysaccharides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D000080506:Sialyl Lewis X Antigen
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D009844:Oligosaccharides; D011134:Polysaccharides; D000080506:Sialyl Lewis X Antigen